AHFS Drug Information (AHFS DI) is a leading source of evidence-based drug information.

AHFS DI is a dependable, comprehensive and objective database for FDA approved drug products. Inclusion of evidence-based data on labelled and unlabelled drug use makes this a valuable reference for healthcare professionals seeking to provide their patients with safe and effective therapy.

AHFS DI is published by the American Society of Health-System Pharmacists (ASHP).

SubscribeContent Updates
Features and Benefits icon

Comprehensive: Highly detailed monographs with extensive information on the chemistry and clinical application of all FDA approved drugs

Features and Benefits icon

Evidence-based: Built on evidence from primary sources and peer reviewed by over 500 pharmacists, physicians and healthcare professionals

Features and Benefits icon

Dependable: Fast and easy access to content that is revalidated, revised and updated regularly as new information arrives

Features and Benefits icon

Objective: The information is compiled without any influence from manufacturers, insurers, regulators or other interested parties

Publication Updates

11 Dec
AHFS Drug Information logo
AHFS Drug Information December 2018 update 

This update contains 8 new monographs, and 47 revised monographs. 

New monographs: Cannabidiol; Cemiplimab-rwlc; Dacomitinib; Galcanezumab-gnlm; Sarecycline; Duvelisib; Elapegademase-lvlr; Omadacycline

Revised monographs: Gemtuzumab; Formoterol; Zonisamide; Cisatracurium; Bendamustine; Lacosamide; Dolutegravir; Vilanterol; Pembrolizumab; Nivolumab; Ibrutinib; Evolocumab; Lumacaftor and Ivacaftor; Enasidenib; Glecaprevir and Pibrentasvir; DAUNOrubicin and Cytarabine; Inotuzumab; Abemaciclib; Acalabrutinib; Dolutegravir and Rilpivirine; Apalutamide; Tobramycin; Methotrexate; Cytarabine; Gentamicin; DAUNOrubicin; fentaNYL; Baclofen; Pancuronium; Succinylcholine; Dantrolene; vinCRIStine; Neuromuscular Blocking Agents General Statement; Verapamil; Atenolol; Atracurium; Amoxicillin; Penicillin G Benzathine; Penicillin G Potassium, Penicillin G Sodium; Penicillin G Procaine; Vecuronium; cefTRIAXone; Flecainide; Sotalol; Rocuronium; Salmeterol; Antiretroviral Agents General Statement 

13 Nov
AHFS Drug Information logo
AHFS Drug Information November 2018 update 

This update contains 12 new monographs, 41 revised monographs and 4 new MedWatch alerts. 

New monographs: Pilocarpine; Migalastat; Lusutrombopag; Sodium Zirconium Cyclosilicate; Tecovirimat; Stiripentol; Antihemophilic Factor (recombinant), PEGylated-aucl; Lanadelumab-flyo; Doravirine; Doravirine, Lamivudine, and Tenofovir Disoproxil; Eravacycline; Fremanezumab-vfrm 

Revised monographs: Bevacizumab; Maraviroc; Tapentadol; Canagliflozin; Dapagliflozin; Empagliflozin; Sofosbuvir, Velpatasvir, and Voxilaprevir; Neratinib; Meropenem and Vaborbactam; Ertugliflozin; Bictegravir, Emtricitabine, and Tenofovir Alafenamide; HYDROcodone; Rabies Vaccine; HYDROmorphone; Levorphanol; Codeine; oxyMORphone; oxyCODONE; Morphine; Methadone; Promethazine; Pentazocine; fentaNYL; Doxylamine; Butorphanol; Nalbuphine; Promethazine; Opiate Agonists General Statement; Antihistamines General Statement; Amoxicillin; Ampicillin; Penicillin V; Preface to Penicillins; Aminopenicillins General Statement; Buprenorphine; metroNIDAZOLE; Clarithromycin; traMADol; Immunization Schedules; Anti-infectives Available from CDC; Immunobiologic Agents Available from CDC 

New MedWatch alerts on the following monographs: Canagliflozin; Dapagliflozin; Empagliflozin; Ertugliflozin

08 Oct
AHFS Drug Information logo
AHFS Drug Information October 2018 update 

This update contains 7 new monographs, 13 revised monographs and 1 new MedWatch alerts. 

New monographs: Dehydrated Alcohol; Iobenguane I 131; Tildrakizumab-asmn; Patisiran; Tafenoquine; Glycopyrronium; Mogamulizumab-kpkc 

Revised monographs: Nevirapine; Enfuvirtide; Bortezomib; Methylnaltrexone; Regorafenib; Naloxegol; Naldemedine; Cyclophosphamide; DOXOrubicin; Aspirin; metroNIDAZOLE; Azithromycin; Thalidomide 

New MedWatch alerts on the following monographs: Azithromycin

14 Sep
AHFS Drug Information logo
AHFS Drug Information September 2018 Update

This update contains 7 new monographs, 35 revised monographs and 5 MedWatch Alerts. 

New monographs: Methoxy Polyethylene Glycol-epoetin Beta; Binimetinib; Encorafenib; Plazomicin; Darunavir, Cobicistat, Emtricitabine and Tenofovir Alafenamide; Ivosidenib; Elagolix 

Revised monographs: Moxifloxacin; Insulin Glargine; Gemifloxacin; Arformoterol; Indacaterol; Enzalutamide; Aclidinium; Vilanterol; Olodaterol; Umeclidinium; Lixisenatide; Sarilumab; Guselkumab; Theophyllines; HYDROmorphone; Erythromycin; Sulfacetamide Sodium; Terbutaline; Albuterol/Levalbuterol; Benztropine; Trihexyphenidyl; Procyclidine; Biperiden; Natamycin; Ephedrine; Ethosuximide; Clindamycin; Lincomycin; Isoproterenol; Hyoscyamine; Atropine; Ciprofloxacin; Ofloxacin; Salmeterol; levoFLOXacin 

New medwatch alerts on the following monographs: Moxifloxacin; Gemifloxacin; Ciprofloxacin; Ofloxacin; levoFLOXacin. 

14 Aug
AHFS Drug Information logo
AHFS Drug Information August 2018 update

This update contains 6 new monographs and 15 revised monographs.

New monographs: Factor Xa (recombinant), Inactivated-zhzo; Erenumab-aooe; Avatrombopag; Pegvaliase; Baricitinib; Lofexidine

Revised monographs: Editorial Staff; Crizotinib; PONATinib; Ceritinib; Perampanel; Alectinib; Daclizumab; Avelumab; Durvalumab; Brigatinib; Sodium Nitroprusside; Mebendazole; Primaquine; Riluzole; Albendazole

10 Jul
AHFS Drug Information logo
AHFS Drug Information July 2018 update

This update contains 2 new monographs, 5 new MedWatch alerts and 95 revised monographs.

New monographs: Burosumab-twza, Fostamatinib.

Revised monographs: Dofetilide, Alosetron, Entacapone, Etanercept, miFEPRIStone, inFLIXimab, inFLIXimab-dyyb, Alemtuzumab, Minocycline, Clopidogrel, Tenofovir Disoproxil Fumarate, Bosentan, Doxycycline, Sodium Oxybate, Adalimumab, Emtricitabine, Natalizumab, Lenalidomide, Varenicline, Rasagiline, Ambrisentan, Lisdexamfetamine, Eculizumab, Alvimopan, romiPLOStim, Dronedarone, Tolvaptan, Golimumab, Tapentadol, Vigabatrin, Denosumab, Liraglutide, Fingolimod, Ustekinumab, Pegloticase, Collagenase Clostridium Histolyticum, Ipilimumab, Vandetanib, Belatacept, Apixaban, Tofacitinib, Teduglutide, PONATinib, Pomalidomide, Dolutegravir, Riociguat, Macitentan, Lomitapide, Mipomersen, Apremilast, Pembrolizumab, Idelalisib, Panobinostat, Parathyroid Hormone, Alemtuzumab, Blinatumomab, Alirocumab, Evolocumab, Flibanserin, Atezolizumab, idaruCIZUmab, Metreleptin, Daclizuma, Crisaborole, Oxymetazoline, Brodalumab, Deutetrabenazine, Midostaurin, Safinamide, Dolutegravir and Rilpivirine, HYDROcodone, ISOtretinoin, HYDROmorphone, oxyMORphone, oxycodone,Morphine, Methadone, Neomycin, Bacitracin, Levodopa/Carbidopa, Benzocaine, HYDROcodone, fentaNYL, Propranolol, Testosterone, Polymyxin B, MAO Inhibitors General Statement, Erythromycins General Statement, Insulin Human, Naltrexone, Buprenorphine, cloZAPine, OLANZapine, Selegiline, Rosiglitazone, Thalidomide.

Discontinued monographs: Insulin zinc.

New medwatch alerts on the following monographs: Dolutegravir, Dolutegravir and Rilpivirine, Benzocaine, Pembrolizumab, Atezolizumab.

View more View all content updates